KR101797813B1 - Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient - Google Patents
Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient Download PDFInfo
- Publication number
- KR101797813B1 KR101797813B1 KR1020150098278A KR20150098278A KR101797813B1 KR 101797813 B1 KR101797813 B1 KR 101797813B1 KR 1020150098278 A KR1020150098278 A KR 1020150098278A KR 20150098278 A KR20150098278 A KR 20150098278A KR 101797813 B1 KR101797813 B1 KR 101797813B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- citrus
- bladder cancer
- cell
- comb
- Prior art date
Links
- 235000020971 citrus fruits Nutrition 0.000 title claims abstract description 127
- 241000207199 Citrus Species 0.000 title claims abstract description 125
- 206010005003 Bladder cancer Diseases 0.000 title claims abstract description 99
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims abstract description 95
- 201000005112 urinary bladder cancer Diseases 0.000 title claims abstract description 95
- 239000004480 active ingredient Substances 0.000 title claims abstract description 16
- 235000019226 kombucha tea Nutrition 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title abstract description 39
- 230000006907 apoptotic process Effects 0.000 claims abstract description 54
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 238000000855 fermentation Methods 0.000 claims abstract description 28
- 230000004151 fermentation Effects 0.000 claims abstract description 27
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- 235000020688 green tea extract Nutrition 0.000 claims description 6
- 229940094952 green tea extract Drugs 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 21
- 230000002265 prevention Effects 0.000 abstract description 15
- 230000002147 killing effect Effects 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 271
- 239000006228 supernatant Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 29
- 230000003078 antioxidant effect Effects 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 20
- -1 flavonoid compounds Chemical class 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 15
- 201000009030 Carcinoma Diseases 0.000 description 15
- 229960004203 carnitine Drugs 0.000 description 15
- 235000013824 polyphenols Nutrition 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 150000008442 polyphenolic compounds Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 244000269722 Thea sinensis Species 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 102000003952 Caspase 3 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 6
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 6
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 6
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 5
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 235000006468 Thea sinensis Nutrition 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 108700000707 bcl-2-Associated X Proteins 0.000 description 5
- 102000055102 bcl-2-Associated X Human genes 0.000 description 5
- 210000001520 comb Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000004660 morphological change Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 235000020279 black tea Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001378 electrochemiluminescence detection Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019985 fermented beverage Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- 241000589234 Acetobacter sp. Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 102000004039 Caspase-9 Human genes 0.000 description 3
- 108090000566 Caspase-9 Proteins 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 241000123815 Lutjanus apodus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- PFKYCGAUNWCWNO-UHFFFAOYSA-N 1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 PFKYCGAUNWCWNO-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CUCUKLJLRRAKFN-UHFFFAOYSA-N 7-Hydroxy-(S)-usnate Chemical compound CC12C(=O)C(C(=O)C)C(=O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O CUCUKLJLRRAKFN-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 238000010269 ABTS assay Methods 0.000 description 1
- 206010063746 Accidental death Diseases 0.000 description 1
- 244000235858 Acetobacter xylinum Species 0.000 description 1
- 235000002837 Acetobacter xylinum Nutrition 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000100312 Brettanomyces sp. Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000007989 Effector Caspases Human genes 0.000 description 1
- 108010089510 Effector Caspases Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000001483 Initiator Caspases Human genes 0.000 description 1
- 108010054031 Initiator Caspases Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000235061 Pichia sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241001030170 Zygosaccharomyces sp. Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910001987 mercury nitrate Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002831 nitrogen free-radicals Chemical class 0.000 description 1
- DRXYRSRECMWYAV-UHFFFAOYSA-N nitrooxymercury Chemical compound [Hg+].[O-][N+]([O-])=O DRXYRSRECMWYAV-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000005839 radical cations Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- ICTZCAHDGHPRQR-UHFFFAOYSA-N usnic acid Natural products OC1=C(C)C(O)=C(C(C)=O)C2=C1C1(C)C(O)=C(C(=O)C)C(=O)C=C1O2 ICTZCAHDGHPRQR-UHFFFAOYSA-N 0.000 description 1
- 229940004858 usnic acid Drugs 0.000 description 1
- WEYVVCKOOFYHRW-UHFFFAOYSA-N usninic acid Natural products CC12C(=O)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The present invention relates to a pharmaceutical composition for prevention or treatment of bladder cancer comprising a citrus sub-body fermentation broth as an active ingredient, and a food composition for preventing or improving bladder cancer.
The composition comprising the citrus comb secondary fermentation broth of the present invention as an active ingredient induces apoptosis of bladder cancer cells, particularly non-invasive (superficial) bladder cancer cells, without showing toxicity to normal cells, It exhibits excellent killing effect. Therefore, the citrus comb secondary fermentation broth of the present invention cultured in the presence of citrus juice may be useful as a pharmaceutical composition or a food composition for the prevention or treatment of early bladder cancer.
Description
The present invention relates to a pharmaceutical composition for prevention or treatment of bladder cancer comprising a citrus sub-body fermentation broth as an active ingredient, and a food composition for preventing or improving bladder cancer.
The incidence of cancer is steadily increasing globally, and according to a report by the National Statistical Office (NSO) of major deaths in Korea, it is reported that the cause of death in Korea is cancer, cerebrovascular disease, and heart disease. According to a report from the International Cancer Institute under the World Health Organization, 30% of cancer deaths are due to smoking, 30% are due to dietary factors, 18% are due to chronic infections, and other occupational, genetic, drinking, Hormone, radiation, environmental pollution, etc. are also contributing 1 ~ 5% each.
Among them, bladder cancer was ranked as the 9th highest cancer among male teenage cancer patients in Korea in the year of 2012. As a side effect of surgery for bladder cancer treatment, drug therapy and chemotherapy, digestive system, urinary tract infection, blood system, Bone marrow suppression, leukopenia, and systemic side effects have been reported.
Although the exact cause of bladder cancer is not known, age, smoking, exposure to chemical agents, and bladder stones are known to be risk factors for bladder cancer and are highly likely to recur after surgery (Vinod H. Nargund et al. al ., 2012, Seminars in oncology , 39 (5): 559-572).
The progression stage of bladder cancer is divided into non-invasive (superficial) bladder cancer, superficial invasive bladder cancer and metastatic bladder cancer depending on the extent of bladder muscle invasion, and the shape of non-invasive bladder cancer is the most diagnosed form of bladder cancer . In addition, it has been reported that early diagnosis and appropriate follow-up and treatment of bladder cancer are important for non-invasive (superficial) bladder cancer because of the difficulty of metastasis and recurrence rate of 60 ~ 80% , Yonsei University Graduate School Master's Thesis ).
Cancer cells that invade muscular layer of the bladder are invasive bladder cancer, which is known as cancer that penetrates the muscle layer and invades into the surrounding tissues and is metastasized. The cancer of the last stage, metastatic cancer, Bladder cancer is divided into three stages.
Recently, studies on natural products having physiological activities such as anticancer and antioxidation have been conducted, and research results have been reported that compounds found in natural products induce apoptosis of cancer cells and exhibit anticancer effects (OS Frankfurt et al ., 2003, Anti - cancer Drugs , 14 (7): 555-561).
The process of cell death is largely divided into two pathways: necrosis and apoptosis. The cell death is accompanied by an inflammation reaction when the stimulus is given to the cell by inflow of moisture outside the cell, and the cell is self-destructed by an internal factor or external stimulus, so that the nucleus is fragmented and the cell is fragmented or phagocytes By swallowing the fragments, cell death proceeds without inflammation (H Steller, 1995, Science , 267 (5203): 1445-1449).
Apoptosis is known to be an active death caused by regulation of several genes and expression proteins. It plays an important role in maintaining the homeostasis of cells by removing the cells with risk factors from normal cells (WS Simonet et al., 1997, Cell , 89 (2): 309-319).
During the course of apoptosis, the caspase (cysteine aspartate-specific protease) affects many biochemical and structural changes in cells dying from apoptosis and acts as an important regulator of apoptosis. The classes that act as initiator caspases include caspase-2, caspase-8, caspase-9, caspase-10, And caspase-3, caspase-6, and caspase-7, which act as effector caspases. In addition, PARP (poly-ADP ribose polymerase), which is a representative caspase-3 substrate protein, plays an important role in maintaining DNA repair or gene stability of normal cells. In apoptosis induction, caspase- This decomposition is lost as the degradation takes place (V Schreiber et al ., 2006, Nature Reviews Molecular Cell Biology 7: 517-528).
The mechanism of apoptosis is divided into the extrinsic pathway associated with the receptor of the cell and the intrinsic pathway associated with mitochondria and includes the death receptors, the Bcl-2 family, Apoptosis is regulated by interactions such as caspase (Z Jin et al ., 2005, Cancer biology & therapy , 4 (2): 147-171). In addition, in apoptosis mechanism, anti-apoptotic factor that suppresses cell death and apoptotic factor by the action of pro-apoptotic factor that induces cell death apoptotic cell death.
B-cell lymphoma-2, an anti-apoptotic protein, binds to Bax (Bcl-2-associated X protein) to form a heterodimer to inhibit the activity of Bax Have been reported to interfere with apoptosis or affect caspases.
Bax, a pro-apoptotic protein, increases apoptotic protease activating factor 1 (Apopt-1) by increasing the mitochondrial membrane permeabilization (MOMP) and increasing the release of cytochrome c, (SN Farrow et al ., 1996, Curr Opin Genet Dev , 6 (1): 1): < RTI ID = 45-49)
In addition, phytochemicals such as flavonoids and polyphenols, which are compounds found in natural products, have been studied to inhibit cancer cell proliferation and inhibit cancer cell metastasis. In addition, it is required to research and develop new uses and value-added by using natural materials that can be commonly found in the surrounding area as a raw material (OS Frankfurt et al ., 2010, Febs Journal , 277 (16): 3437-3448, et al ., 2003, Korean Journal of Food Science and Nutrition 32 (2): 217-222).
It is known that citrus fruits, which are used as raw materials for oriental medicine and herbal medicine, contain various components such as flavonoids, carotenoids and coumarins. The major citric-derived flavonoid compounds are naringin and hesperidin and their aglycone forms, naringenin and hesperetin, as well as rutin, nobiletin, ), And tangeretin, and it is also effective in improving the vascular disease by blood cholesterol and neutral lipid inhibition effect, improving liver disease including liver disease, anti-cancer effect by inhibiting cancer cell proliferation, antioxidants to inhibit lipid peroxidation, antibacterial action, anti-inflammatory and antiallergic, immune-enhancing activity there are a variety of physiological functions, reported such activity (chajaeyoung et al, 2001, J. Korean Soc . Agric. Chem. Biotchnol., 44 (2): 122-128).
(CW Hesseltine, 1983, Nutr Rev , 41 (10)) was one of the drinks known as traditional fermented beverages in Russia, : 293-301). In the United States, it is known that there is a refreshing taste, detoxification effect, chronic fatigue, constipation, and health improvement and medical treatment effect of the cow bug in the United States. In Korea, fermented beverage known as black tea mushroom is known to have detoxification activity, antimicrobial activity and antioxidant activity have.
It is also known that glucuronic acid, vitamins B1, B2, and B2 are effective for pain relief of arthritis, blood pressure reduction, increase of T cells, constipation relief, digestive or metabolic diseases, B6 and antibiotic-active usnic acid, and antioxidant activity (KH Steinkraus et al ., 1996, Acta Biotechnol. , 16 (2-3): 199-205; R Srinivasan et al ., 1997, Journal of general internal medicine , 12 (10): 643-645).
Examples of the Acetobacter sp. Are Acetobacter Xylinum, Saccharomyces sp., Zygosaccharomyces sp., And the like. Examples of the Acetobacter sp. , Yeasts such as Torulopsis sp., Pichia sp., And Brettanomyces sp. Are present.
Acetobacter sp. And yeast are in a symbiotic relationship with each other. These strains interact simultaneously and fermentation proceeds to produce acetic acid, glucuronic acid, Amino acids and cellulose pellicle. Recent researches on comb-bacterium have shown that the effect of down-regulation of prostate cancer neovascularization and the prevention of toxic substances in hepatocytes (SC Chu. Et al., 2006, Food Chem , 98 (3): 502-507; T Srihari et al ., 2013, Biomedicine & Preventive Nutrition , 3 (1): 53-58; S Bhattacharya et al ., 2011, Indian Journal of Experimental Biology , 49: 511-524).
Although tea is mostly used when cultivating kombu tea, green tea has a higher content of tea catechin than fermented tea such as black tea or oolong tea. Tea catechin is used as an antioxidant to prevent food from deteriorating (MWL Koo et al ., 2004, Eur J Pharmacol , 500 (1-3): 177). However, it has been reported that serum lipid components such as body weight, waist circumference, -185; Korean Patent No. 10-0482308).
Under these circumstances, the inventors of the present invention have made efforts to find a natural product having an anticancer effect against bladder cancer and a low side effect, and as a result, it has been found that a citrus fruit supplement solution containing green tea extract and citrus juice is effective in killing bladder cancer cells And the present invention has been completed.
It is an object of the present invention to provide a pharmaceutical composition for preventing or treating bladder cancer, which comprises a citrus comb secondary fermentation broth as an active ingredient.
It is another object of the present invention to provide a food composition for prevention or improvement of bladder cancer, which comprises a citrus comb secondary fermentation broth as an active ingredient.
In one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating bladder cancer, which comprises a citrus comb secondary fermentation broth as an active ingredient.
The term "Kombucha (K)" in the present invention is a fermented black tea drink, which is one of the traditional fermented beverages in Russia which is fermented by putting a fungus called tea fungus into a black tea extract. / ≪ / RTI > and adding the sugar to the green tea and fermenting it.
In one embodiment of the present invention, the Comvita is prepared by adding a commercial comb supplement and a hot water-extracted green tea extract containing a pellicle, and 5 to 15% (w / v) (V / v) of the total composition, and the pellicle has a volume of 6.25 to 50% (v / v), which is 1/2 to 1/16 of the volume. w / v) at a temperature of 28 to 35 DEG C for 5 to 10 days (Example 1-1, Fig. 1 and Fig. 3).
In the present invention, the term "Citrus Kombucha (CK) fermentation broth" is a fermentation broth fermented by adding citrus juice to the comb culture.
The citrus comb secondary fermentation broth may be prepared by: 1) adding a green tea extract and a 5 to 15% (w / v) sugar of the whole composition to a pre-culture by stirring the mixture; 2) cooling extracting the pre-cultured comb cells of step 1) at 5 to 15 캜; And 3) 5 to 20% (v / v), 0.01 to 0.5% (v / v) acetate, 6.25 to 50% (w / v) pellicle of the comb secondary culture obtained through the pre- (Citric acid solution) and 5 to 50% (v / v) citrus solution for 5 to 10 days (Examples 1-1, 2 and 3).
The term "bladder cancer" in the present invention refers to a malignant tumor that occurs in the bladder. The bladder cancer is largely localized only in the bladder mucosa or the submucosal layer. Therefore, ) Bladder cancer, and bladder cancer is a muscle-invasive bladder cancer that requires bladder removal to completely remove the tumor by invading the muscle layer, and metastatic bladder cancer.
The term "prevention" in the present invention means all actions that inhibit or delay the generation, spread and recurrence of bladder cancer by the administration of the pharmaceutical composition according to the present invention, and "treatment" And all actions that alleviate or ameliorate the symptoms of the affected individuals.
Cancers which can be prevented or treated by the composition of the present invention include, but are not limited to, bladder cancer, preferably non-invasive (superficial) bladder cancer.
Preferably, the prevention or treatment of cancer can be accomplished by the apoptosis of cancer cells induced by the citrus comb secondary fermentation broth according to the present invention. The above-mentioned "apoptosis" is a kind of programmed cell death (PCD), in which abnormal cells, damaged cells and aged cells are killed and killed by the biological program inputted into our body, . Such apoptosis is distinguished from cell death caused by stimulation such as burns, scabs, and poisons, such as necrosis, which is the death or accidental death of a cell. That is, apoptosis is an active death of a cell that is regulated by a protein expressed from a specific gene. While apoptosis occurs chaotically, apoptosis occurs in an orderly fashion in a short time. Specifically, apoptosis begins with the contraction of the cell, creating a gap between the adjacent cells, and DNA, which is a genetic material in the nucleus of the cell in the process of dying, is regularly cleaved into fragments. Ultimately, the entire cell called the apoptotic body is also broken up, and it is killed by other cells around it. It is involved in the formation of the human body during the early development of the human body. In adults, it is responsible for eliminating normal cells when they become senescent, or removing cells with abnormalities. The apoptosis is distinguished from PCD in that it also occurs in cases other than PCD, and is related to cell death due to cancer cell death, viral infection, drug, and radiation.
According to a specific embodiment of the present invention, it was confirmed that the composition of the present invention, for example, citrus squamous carcass did not show cytotoxicity against normal cells (RAW 264.7) but showed killing effect on bladder cancer cell lines (T24 and 5637) , Especially T24 cells, a non-invasive (superficial) bladder cancer cell line (FIGS. 4 and 5). In addition, it was confirmed that the treatment of the composition induces apoptosis and induces apoptosis. In particular, in the case of non-invasive (superficial) bladder cancer cells (T24), apoptosis is effectively induced in the treatment of citrus subspecies, Activity was further confirmed (FIG. 11). Further, by confirming the expression of proteins involved in the apoptosis of cancer cells, it can be confirmed once again that the composition of the present invention induces apoptosis of cancer cells through the external pathway through the death receptor and the internal pathway in the mitochondria (Fig. 13).
The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" of the present invention means that it exhibits properties that are not toxic to the cells or humans exposed to the composition. Such carriers may be used without limitation as long as they are known in the art such as buffers, preservatives, wetting agents, solubilizers, isotonic agents, stabilizers, bases, excipients and lubricants.
In addition, the pharmaceutical composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method have. Furthermore, it can be used in the form of an external preparation for skin in the form of ointments, lotions, spray agents, patches, creams, powders, suspensions, gels or gels. Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use may include various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are simple diluents commonly used in suspension, liquid solutions, emulsions and syrups have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
Meanwhile, the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount " of the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, The type of cancer, the severity, the activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including the drugs used concurrently or concurrently and other factors well known in the medical arts . The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
In particular, the effective amount of the citrus sub-body fermentation broth contained in the composition of the present invention may vary depending on the age, sex, and body weight of the patient. Generally, the citrus comb sub-composition of the present invention is 0.001 To 100 mg, preferably 1 to 10 mg, more preferably 1 to 5 mg per kg of body weight per day or every other day, or one to three divided doses per day. However, the dosage may not be limited in any way because it may be increased or decreased depending on route of administration, severity of disease, sex, weight, age, and the like.
The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
In another aspect, the present invention provides a method for preventing or treating bladder cancer, comprising administering a citrus sub-fermentation broth to a subject in need thereof.
The term "individual" of the present invention means a mammal such as a monkey, a cow, a horse, a sheep, a pig, a chicken, a turkey, a quail, a cat, a dog, a mouse, a rat, a rabbit or a guinea pig , And the cancer can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to a subject. The pharmaceutical composition of the present invention can be administered in parallel with existing therapeutic agents.
The term "administering" of the present invention means providing the patient with the desired substance in any suitable manner, and the administration route of the composition of the present invention may be administered through any conventional route so long as it can reach the target tissue have. But are not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrathecal, rectal. In addition, the pharmaceutical composition of the present invention may be administered by any device capable of moving the active substance to the target cell. The preferred modes of administration and formulations are intravenous, subcutaneous, intradermal, intramuscular, and drip injections. The injectable solution may be a non-aqueous solvent such as an aqueous solvent such as a physiological saline solution or a ring gel solution, a vegetable oil, a higher fatty acid ester (e.g., oleic acid), an alcohol (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.) (For example, ascorbic acid, sodium hydrogen sulfite, sodium pyrophosphate, BHA, tocopherol, EDTA and the like), an emulsifier, a buffer for pH control, a microbial growth inhibitor And a pharmaceutical carrier such as a preservative (e.g., mercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
The pharmaceutical composition of the present invention may further include a known anticancer agent in addition to the citrus comb secondary fermentation liquid as an active ingredient and may be used in combination with other known treatments for the treatment of these diseases. Other treatments include, but are not limited to, chemotherapy, radiation therapy, hormone therapy, bone marrow transplantation, stem cell replacement therapy, other biological therapies, immunotherapy, and the like.
Examples of anticancer agents that can be included in the pharmaceutical composition of the present invention include DNA alkylating agents such as mechloethamine, chlorambucil, phenylalanine, mustard, cyclophosphate, Cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin cisplatin and carboplatin; The anticancer antibiotics include dactinomycin (actinomycin D), doxorubicin (adriamycin), daunorubicin, idarubicin, mitoxantrone, Plicamycin, mitomycin C, and bleomycin; And plant alkaloids such as vincristine, vinblastine, paclitaxel, docetaxel, etoposide, teniposide, topotecan, And iridotecan, but are not limited thereto.
In another aspect, the present invention provides a food composition for prevention or amelioration of bladder cancer, which comprises a citrus comb secondary fermentation broth as an active ingredient. When the composition of the present invention is used as a food composition, the citrus subterranean fermentation broth can be used as it is, or can be used in combination with other food or food ingredients, and can be suitably used according to ordinary methods. The composition may contain a food-acceptable food-aid additive in addition to the active ingredient, and the amount of the active ingredient to be mixed may be suitably determined according to the purpose of use (prevention, health or therapeutic treatment).
As used herein, the term "food-aid additive " refers to a component that can be added to foods in a supplementary manner, and is appropriately selected and used by those skilled in the art as added to produce health functional foods of each formulation. Examples of food-aid additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, , a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, and a carbonating agent used in a carbonated drink. However, the types of the food auxiliary additives of the present invention are not limited by these examples.
A health functional food may be included in the food composition of the present invention. The term "health functional food " as used in the present invention refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. Here, 'functional' refers to the structure and function of the human body to obtain nutritional effects and obtain useful effects for health use such as physiological action. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The composition for food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has the advantage that there is no side effect that may occur when a drug is used for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to enhance the effectiveness of anticancer drugs.
There is no limitation on the kind of health food to which the composition of the present invention can be used. In addition, the composition comprising the citrus comb secondary fermentation broth of the present invention as an active ingredient may be prepared by mixing other suitable auxiliary ingredients and known additives, which may be contained in health functional foods, according to the selection of a person skilled in the art. Examples of foods that can be added include dairy products, such as meat, sausage, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Vitamin complex, and the like, and they may be added to juice, tea, jelly, juice and the like prepared from the citrus comb supplementary fermentation broth according to the present invention as a main ingredient.
The citrus comb secondary fermentation broth of the present invention can be used as a pharmaceutical composition or a food composition because it can be less harmful than general synthetic compounds and thus can be safely used in pharmaceutical compositions and health functional foods have.
The composition comprising the citrus comb secondary fermentation broth of the present invention as an active ingredient induces apoptosis of bladder cancer cells, particularly non-invasive (superficial) bladder cancer cells, without showing toxicity to normal cells, It exhibits excellent killing effect. Therefore, the citrus comb secondary fermentation broth of the present invention cultured in the presence of citrus juice may be useful as a pharmaceutical composition or a food composition for the prevention or treatment of early bladder cancer.
Fig. 1 is a flow diagram schematically showing a step of producing a Kombucha fermentation broth of the present invention.
FIG. 2 is a flow diagram schematically showing a step of producing a citrus Kombucha fermentation broth of the present invention.
FIG. 3 is a photograph showing a sample of a fermented beverage of the present invention.
FIG. 4 is a graph showing the results of cytotoxicity test according to the concentration of the comb and carnitine secondary to the present invention (RAW 264.7 cell). FIG.
FIG. 5 is a graph showing the results of inhibition of cell proliferation according to the concentration of comb and carnitine secondary to the non-invasive (superficial) bladder cancer cell (T24 cell) of the present invention.
FIG. 6 is a graph showing the results of inhibiting cell proliferation according to the concentration of comb and carnitine secondary to the present invention on high-risk superficial bladder cancer cells (5637 cells).
FIG. 7 is a photograph showing a morphological change of a T24 cell of a non-invasive (superficial) bladder cancer cell line according to the concentration of the Comvatus (A) and Citrus subunit (B) of the present invention under a microscope.
FIG. 8 is a photograph showing a morphological change of 5637 cells of a high-risk superficial bladder cancer cell line according to the concentration of the Comvatus (A) and the Citrus subunit (B) of the present invention under a microscope.
FIG. 9 is a graph showing the degree of migration of non-invasive (superficial) bladder cancer cell line T24 cells according to the concentration of the combus subtype (A) and the citrus combus subtype (B) of the present invention through a wound healing assay It's a picture.
FIG. 10 is a microscopic photograph showing the degree of migration of high-risk superficial bladder cancer cell line 5637 cells according to the concentration of the combus subtype (A) and the citrus combus subtype (B) of the present invention through a wound healing assay to be.
FIG. 11 is a graph showing the degree of apoptosis by quantifying the degree of apoptosis of non-invasive (superficial) bladder cancer cell line T24 cells according to the concentration of a comb and a citrus sub-anchor of the present invention.
FIG. 12 is a graph showing quantitation of apoptosis-induced apoptosis of high-risk superficial bladder cancer cell line 5637 cells according to the concentration of comb and carnitine secondary soma of the present invention.
FIG. 13 is a graph showing the ability of the non-invasive (superficial) bladder cancer cell line T24 cells according to the present invention to control the expression of apoptosis-related proteins according to the concentrations of the comb and carnitine secondary soma.
FIG. 14 is a graph showing the ability of the present invention to control the expression of apoptosis-related protein on the high-risk superficial bladder cancer cell line 5637 cells according to the concentrations of comb and carnitine secondary.
Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
Example One: Kom Bucha Culture and sample preparation
Example 1-1: Kom Bucha culture
The Kombucha used in the present invention is a domestic domestic Kombucha, which is purchased and sold in the private sector through the Internet (www.auction.co.kr).
In the case of Comvuka, 900 ml of green tea extract and 90 g of sugar were added and stirred, and then pre-cultured, 100 ml of the origin kombucha culture obtained after the pre-culture and 18 g of the pellicle produced by the pre-culture fermentation were added at a volume of 1/4 of the volume and cultured at 30 ° C for 10 days. In addition, as shown in FIG. 2, the Citrus comb subspecies were prepared by pre-incubation after mixing 700 ml of green comb extract and 90 g of sugar, which contains a pellicle for commercial use, and incubated at the
The citrus juice used in the present invention was obtained by using the one produced in Ilhwa, Korea.
Example 1-2: Sample Preparation
Kombicha and Citrus Kombucha samples were prepared for antioxidant and total polyphenol contents measurement and for cell experiments.
Specifically, for the antioxidation and total polyphenol contents measurement, supernatants obtained after centrifugation of comb and carnitine at 20,000 rpm for 12 minutes were prepared. In the cell experiments, Each supernatant obtained after the minute centrifugation was filtered using a syringe filter unit (pore size 45 μm) and diluted in medium (RPMI-1640).
Example 2: Culture of cell line
T24 cells, which are non-invasive (superficial) bladder cancer cell lines used in the present invention, and 5637 cells that are high-risk superficial bladder cancer cells were purchased from Korean Cell Line Bank. The T24 cells and 5637 cells were cultured at 37 ° C in 5% (Sigma-Aldrich) supplemented with fetal bovine serum (FBS) and 1% penicillin (GIBCO Inc.).
RAW 264.7 cells used in the present invention were purchased from ATCC (American Type Culture Collection, Manassas, Va., USA) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT, USA) glutamine, and 100 mg / L penicillin-streptomycin (Hyclone Laboratories).
Example 3: Kombucha Citrus Kombucha Antioxidant activity measurement
DPPH radical scavenging activity and ABTS radical cation scavenging activity were measured to determine the antioxidant activity of Kombucha K and Citrus Kombucha CK. In addition, the antioxidant ability of the sample is not directly measured, but since the antioxidant ability contained in the sample can be predicted, the total polyphenol content was measured as one of widely used methods for antioxidant research.
Example 3-1: DPPH Radical Scatters Measure
DPPH (1,1-diphenyl-2-picryl hydrazyl) is a dark purple colored ganic nitrogen free radical. It shows absorbance in the ethanol solution state. When it comes into contact with a substance having antioxidative activity, It is characterized by the irreversible conversion of a stable compound that is reduced while accepting electrons of hydrogen radicals, and the deep violet is thinned.
Thus, a DPPH assay (DPPH assay) was conducted to measure the rapid and simple free radical scavenging ability as a widely used method for measuring antioxidant ability. Vitamin C (ascorbic acid) was used as a control group.
More specifically, 4 ml of a 0.2 mM DPPH solution dissolved in ethanol was added to 1 ml of each sample of the comb-tertiary and citrus subcombinations, followed by reaction at room temperature for 20 minutes. The absorbance values at 517 nm wavelength were measured using an ELISA microplate reader (Versa Max, USA) and the results were shown by the following equation.
(DPPH radical scavenging activity, (%)) = [1- (absorbance of control group without addition of combs or citrus sub-samples)] × 100
As a result, the DPPH radical scavenging activity of citrus squam carcinoma supplemented with the Comvatus culture medium and the citrus juice supplement was 1 mg / ml of squid carcass and citrus squam carbeta as shown in Table 1 below, and the DPPH radical scavenging activity was 87.9 % And 91.2% respectively.
As a result, the antioxidant activity of both the comb and the citrus combs was superior to that of the control group, vitamin C. In particular, the free radical scavenging activity of the citrus combs supplemented with citrus fluids versus comb , The antioxidant activity of citrus squam carcinoma was found to be superior to that of comb carcinoma.
Example 3-2: ABTS Radical Cation Scatters Measure
ABTS (3-ethylbenzothiazoline-6-sulphonic acid) assay is a method to measure the abilities of antioxidants to cations (ABTS · +). Potassium persulfate persulfate to form a green ABTS radical, and the resulting ABTS radical is reduced to a colorless substance by receiving electrons from the antioxidant substance.
Thus, the ABTS assay capable of measuring the antioxidant activity was performed on the basis of the above principle, and the ABTS radical cation scavenging activity of the present invention was measured. Vitamin C (ascorbic acid) was used as a control group.
Specifically, ABTS radical cationic scavenging activity was measured by incubating 7.4 mM ABTS and 2.6 mM potassium persulfate in a dark place overnight to form ABTS cations. The solution was adjusted to have an absorbance value of 1.4 to 1.5 at a wavelength of 735 nm Diluted with distilled water and used.
100 μl of each sample of Kombucha and Citruscomb and 900 μl of ABTS solution were added and left for 30 minutes, and then measured at 735 nm wavelength using an ELISA reader. The results are shown in the following formula.
Absorbance of ABTS radical cation scavenging activity (%) = [1- (absorbance of control group without addition of combs or citrus sub-sample)] / 100
As a result, the ABTS radical cation-scavenging activity of citrus squam carcinoma supplemented with the comb-secondary culture and the citrus juice was found to be 1 mg / ml of the comb and carnitine secondary metabolites as shown in Table 2 below, and the ABTS radical cation- 78.78% and 94.59%, respectively.
The antioxidative activity of citrus squam carcinoma was found to be superior to that of the carcinoma squam carcinoma by confirming that the free radical scavenging activity of citrus squam carcinoma supplemented with citrus juice was higher than that of combus carota. But also the antioxidant activity of vitamin C, which is similar to the control vitamin C.
Example 3-3: Total polyphenol content (total polyphenol content measurement
Since several hydroxyl groups substituted on the benzene ring of the polyphenol compound participate in the reduction reaction with free radicals, the antioxidative activity is exhibited. Therefore, as the total polyphenol content in the sample increases, the antioxidant activity (Y Park et al ., 2008, Food Science and Biotechnology 17 (2): 251-256).
Therefore, the antioxidant ability of the sample is not directly measured. However, since the antioxidant ability contained in the sample can be predicted, the total polyphenol content was measured as a widely used method for antioxidant research.
Specifically, 1 ml of a sample of each of Combacca and Citruscomb subunit was mixed with 1 ml of a 10% folin-ciocalteu's phenol regent and 1 ml of a 2% sodium carbonate solution, Absorbance was measured at a wavelength of 750 nm using an ELISA reader.
The total phenolic content was calculated using a standard curve prepared using tannic acid, and the total polyphenol content was expressed as 쨉 g / ml per sample weight.
As a result, as shown in Table 3 below, the total polyphenol contents of Comvatus and Citrus subunit were 17.82 μg / ml and 28.62 μg / ml, respectively, when expressed as equivalents of tannic acid per μg.
The total polyphenol content of Citrus buccal supplemented with citrus juice was higher than that of.
The results of the antioxidant activity measurement showed that the total polyphenol content of citrus squam carcinoma supplemented with citrus juice was higher than that of Combauchi, and the antioxidant activity was excellent. Thus, cell membrane destruction, enzyme inactivation, lipid oxidation, DNA denaturation, And reactive oxygen species (ROS), which cause a serious pathological disorder such as atherosclerosis, autoimmune disease, including cancer, by causing potential cell damage such as cell senescence, It can be efficiently removed.
Example 4: Kombucha Citrus Kombucha Cytotoxicity measurement
(MTT assay, 3- (4,5-dimethylthiazol-2-yl) -2,5-dimethyl-thiazol-2-yl) -acetic acid was used to measure the inhibition of cell proliferation by treatment with Kombucha, K and Citrus Kombucha diphenyltetrazolium bromide assay).
Example 4-1: For normal cells (RAW 264.7) Kombucha Citrus Kombucha Cytotoxicity measurement
First, MTT assay was performed to determine the effect of Kombucha and Citrus Kombucha on the cell viability of normal cell RAW 264.7 cells.
Specifically, RAW 264.7 cells were seeded in a 96-well plate at a density of 1 × 10 4 cells / well, and the somatic and somatic sub-samples were divided into 0, 1, 2, 4, 6, 8 mg / ml, and cultured for 24 hours. After culturing, 10 쨉 l of 5 mg / ml MTT reagent (Thiazolyl Blue Tetrazolium Bromide) was added to each well and cultured for 1 hour, and the medium was removed. 100 쨉 l of DMSO (dimethyl sulfoxide) was dispensed into each well from which the medium had been removed. All of the formazan produced by the MTT reagent was dissolved in each well, and the absorbance at a wavelength of 560 nm was measured with an ELISA reader Were measured. At this time, the cell viability was expressed as a percentage of the absorbance of the control group (untreated group) in the respective samples of the comb and carcass sub-samples.
As shown in FIG. 4, when the toxin of the comb and the citrus comb subspecies were treated at the concentrations of 0, 1, 2, 4 and 6 mg / ml, respectively, the survival rate of 100 %, Respectively. In the case of treating each of the comb and carcinoma subculture samples at a concentration of 8 mg / ml, the survival rate was 80% or more and the toxicity was about 20% or less, which greatly influenced the cell survival rate of normal cells RAW 264.7 cells Respectively.
Example 4-2: Nasal invasion (Superficial) for bladder cancer cells (T24 cell) Kombucha Citrus Kombucha Cytotoxicity measurement
Of non-invasive (superficial) bladder cancer cells (T24 cells) following treatment with Kombucha and Citrus Kombucha MTT assay was performed to measure cell proliferation inhibition. At this time, the treatment concentrations of the comb and carnitine subunits were 0, 1, 2, 4, 6 and 8 mg / ml, which do not significantly affect the cell viability of the normal cell RAW 264.7 cells in Example 4-1 Respectively.
Specifically, T24 cells were seeded in a 96-well plate at a density of 1 × 10 4 cells / well, and the cells were inoculated with 0, 1, 2, 4, 6 , 8 mg / ml, and cultured for 24 hours. After culturing, 10 쨉 l of 5 mg / ml MTT reagent was added to each well, followed by incubation for 1 hour, and the medium was removed. 100 쨉 l of DMSO (dimethyl sulfoxide) was dispensed into each of the wells from which the medium had been removed. All of the formazan produced in each well was dissolved and the absorbance at 560 nm was measured with an ELISA reader. At this time, the cell proliferation rate was compared with the cell proliferation according to the concentration of the test group treated with each of the comb and carcass sub-samples, based on 100% of the cell viability of the control group (untreated group).
As shown in FIG. 5, the T24 cells of bladder invasion (superficial) bladder cancer cells were treated with the comb cells and the citrus comb cells at the concentrations of 1, 2, 4, 6 and 8 mg / Survival rates were 82.57%, 69.01%, 50.12%, 33.47% and 26.09%, respectively, and the survival rate was 81.96%, 72.77%, 50.36%, 19.49% and 13.44% respectively when treated with Citrus squamous carcass p < 0.05).
These results suggest that both the comb and the citrus sub - cultures inhibit the proliferation of non - invasive (superficial) bladder cancer cells as the treatment concentration increases. Especially, when the citrus comb sub - (Superficial) bladder cancer cell proliferation compared to the control group.
Example 4-3: High-risk superficial bladder cancer cells (5637 cells) Kombucha Cytotoxicity measurement of citrus squam carcinoma
High-risk superficial bladder cancer cells (5637 cells) following treatment with Kombucha and Citrus Kombucha MTT assay was performed to measure cell proliferation inhibition. At this time, the treatment concentrations of the comb and carnitine subunits were 0, 1, 2, 4, 6 and 8 mg / ml, which do not significantly affect the cell viability of the normal cell RAW 264.7 cells in Example 4-1 Respectively.
Specifically, 5637 cells were seeded in a 96-well plate at a density of 1 × 10 4 cells / well, and the cells were inoculated with 0, 1, 2, 4, 6 , 8 mg / ml, and cultured for 24 hours. After culturing, 10 쨉 l of 5 mg / ml MTT reagent was added to each well, followed by incubation for 1 hour, and the medium was removed. 100 쨉 l of DMSO (dimethyl sulfoxide) was dispensed into each of the wells from which the medium had been removed. All of the formazan produced in each well was dissolved and the absorbance at 560 nm was measured with an ELISA reader. At this time, the cell proliferation rate was compared with the cell proliferation according to the concentration of the test group treated with each of the comb and carcass sub-samples, based on 100% of the cell viability of the control group (untreated group).
As shown in FIG. 6, when the comb secondary cells were treated with high-risk superficial bladder cancer cells 5637 cells at a concentration of 1, 2, 4, 6 and 8 mg / ml, Survival rates were 84.22%, 84.71%, 85.63%, 80.63% and 68.22%, respectively, and 82.5%, 74.24%, 76.03%, 65.71% and 35.87% survival rates of citrus subspecific treatment were respectively ( p < 0.05).
As a result, it was found that high-risk superficial bladder cancer cells (TGF-β1) and high-dose superficial bladder cancer cells (TGF-β) 5637 cells also inhibited cell proliferation. In addition, it was found that the treatment of citrus squam carcinoma significantly inhibited the proliferation of superficial superficial bladder cancer cells compared to the case of treatment of squamous cell carcinoma.
The results of cytotoxicity measurements of the comb and carnitine mutants show that both comb and carnitine are not toxic to normal cells, and that T24 cells, which are non-invasive (superficial) bladder cancer cells, and high-risk superficial bladder cancer cells 5637 cells were inhibited. In addition, the bladder cancer cells were found to have a higher cell proliferation inhibition rate than the humps.
In addition, the inhibition rate of cell proliferation was higher for the T24 cells of the non-invasive (superficial) bladder cancer cells than the 5637 cells of the high-risk superficial bladder cancer cells, and the inhibition rate of the cell proliferation of the citrus sub- . Thus, it can be seen that the citrus comb secondary of the present invention can be advantageously used for the prevention or treatment of bladder cancer which is an early bladder cancer.
Example 5: Kombucha, K and Citrus To Citrus Kombucha (CK) Observation of cell morphology of bladder cancer
Example 5-1: Kombucha Citrus Kom Bucha Following Nasal invasion (Superficiality) Observation of cell morphology of bladder cancer cells (T24 cell)
In order to confirm the cell morphology of non-invasive (superficial) bladder cancer cells (T24 cells) according to the concentration of the comb and carnitine secondary metabolites of the present invention, 6 × 10 5 / well lt; RTI ID = 0.0 > T24 cells were subcultured, and each of Combacca and Citrus subspecies samples were treated at 0, 1, 2, 4, 6, 8 mg / ml and cultured for 24 hours. After culturing for 24 hours, the cells were observed with a 100 × (0.25) PhP magnification using an inverted microscope (CK × 40-CPG30, Olympus, Japan).
As a result, as shown in Fig. 7A, when T4 cells as non-invasive (superficial) bladder cancer cells were treated with Comvatus at a concentration of 8 mg / ml, the number of cancer cells was decreased, but morphological changes were not observed. On the other hand, as shown in FIG. 7B, it was observed that when the citrus subsp. Subspecies were treated at a concentration of 6 and 8 mg / ml, the shape including the decrease of the number of cancer cells was changed.
Example 5-2: Kombucha Citrus Kom Bucha Of high-risk superficial bladder cancer cells (5637 cells)
To examine the cell morphology of the high-risk superficial bladder cancer cells (5637 cells) according to the concentration of the comvatus and citrus sub-aberration of the present invention, 6 × 10 5 cells / well in a 6-well plate ) As the number of cells 5637 cells were subcultured, and the cells were subjected to the treatment with a solution of 0, 1, 2, 4, 6, and 8 mg / ml of each of Combacca and Citrus subspecies for 24 hours. After culturing for 24 hours, the cells were observed with a 100 × (0.25) PhP magnification using an inverted microscope (CK × 40-CPG30, Olympus, Japan).
As a result, as shown in FIG. 8A, when cancer cells were treated with high-risk superficial bladder cancer cells, 5637 cells, the number of cancer cells decreased in a concentration-dependent manner, but no significant morphological changes were observed. On the other hand, as shown in FIG. 8B, it was observed that when the citrus squam carcass was treated at a concentration of 8 mg / ml, the morphology was slightly changed, including the decrease in the number of cancer cells.
As a result of observing the cell morphology of bladder cancer according to the present invention, the concentration and adherence of cancer cells are lost by the treatment of high concentration (6 and 8 ㎎ / ㎖) of citrus fruits, And the morphological changes of cancer cells were observed.
Example 6: Kombucha, K and Citrus Citrus Kombucha, CK Evaluation of effect on bladder cancer cell mobility
Example 6-1: Kombucha Citrus Kombucha Nasal invasion (Superficiality) Evaluation of effect on bladder cancer cell (T24 cell) mobility
In order to confirm the mobility of non-invasive (superficial) bladder cancer cells (T24 cells) according to the concentrations of the comb and carnitine secondary cells of the present invention, a scratch was performed to examine the wound healing phenomenon healing assay. At this time, the time point at which the cells were removed was 0 hours.
Specifically, in a 6-well plate, cells were seeded at 2 × 10 5 cells / well T24 cells were dispensed and cultured until the cells reached a subconfluence state. When the cells reached the subconfluence state, the cells were scratched by scraping to the end of a 200 l pipet tip to remove the cells. Subsequently, the upper layer medium was removed from wells with scratched T24 cells. The supernatant of the supernatant was removed from the supernatant and the supernatant was added to the supernatant. The supernatant of the supernatant and the supernatant of the supernatant were added to the supernatant, and the supernatant was diluted to a concentration of 0, 1, 2, 4, 6 and 8 mg / ml. After 24 hours, changes in cell mobility were observed at a magnification of 40 × (0.13) PhP using an inverted microscope (CK × 40-CPG30, Olympus, Japan).
As a result, as shown in Fig. 9, when the T24 cells as non-invasive (superficial) bladder cancer cells were treated as a control group (no sample added, untreated sample treated, 0 mg / ml) However, it was confirmed that migration of cells was suppressed with increasing concentration of comb and carnitine. In particular, it was confirmed that the cell mobility was more remarkably suppressed when the citrus subtilis was treated at the concentrations of 4, 6 and 8 mg / ml compared to the comb (supernatant) (Fig. 9B).
Example 6-2: Kombucha Citrus Kombucha Evaluation of effects on high-risk superficial bladder cancer cell (5637 cell) mobility
In order to confirm the mobility of the high-risk superficial bladder cancer cells (5637 cells) according to the concentration of the comb bacterium and the citrus sub-bacterium of the present invention, a wound healing assay ) Were performed. At this time, the time point at which the cells were removed was 0 hours.
Specifically, in a 6-well plate, cells were seeded at 2 × 10 5 cells / well 5637 cells were seeded and cultured until the cells reached a subconfluence state. When the cells reached the subconfluence state, the cells were scratched by scraping to the end of a 200 l pipet tip to remove the cells. Subsequently, the upper layer of the medium was removed from the wells containing the scratched 5637 cells. The supernatant of the supernatant was removed from the supernatant and the supernatant was added to the supernatant. The supernatant of the supernatant and the supernatant of the supernatant were added to the supernatant, and the supernatant was diluted to a concentration of 0, 1, 2, 4, 6 and 8 mg / ml. After 24 hours, changes in cell mobility were observed at a magnification of 40 × (0.13) PhP using an inverted microscope (CK × 40-CPG30, Olympus, Japan).
As a result, as shown in FIG. 10, when 5637 cells of high-risk superficial bladder cancer cells were treated as control (no sample added, untreated sample treated 0 mg / ml), migration of cells after 24 hours was significantly increased , But it was confirmed that migration of the cells was inhibited when the comb-carcass was treated at a concentration of 8 mg / ml. In particular, it was confirmed that the cell mobility was more remarkably suppressed in a concentration-dependent manner when Citrus quadratus was treated as compared to Comb (Fig. 10B).
As a result of the evaluation of the effect on the bladder cancer cell mobility of the above-mentioned Comvatus and Citrus subsp. Carcass, it was confirmed that both of the somatic invasive (superficial) bladder cancer cell T24 cells and the high-risk superficial bladder cancer cell 5637 cell Mobility was suppressed. In addition, it was found that the citrus comb subunit compared to comb secondary to bladder cancer cells significantly inhibited cell migration.
In addition, it was confirmed that T24 cells, which are non-invasive (superficial) bladder cancer cells, have better inhibitory effect on cell mobility than that of 5637 cells, which are high-risk superficial bladder cancer cells. Thus, it can be seen that the citrus comb secondary of the present invention can be advantageously used for the prevention or treatment of bladder cancer which is an early bladder cancer.
Example 7: Kombucha Citrus Kom Bucha Treatment of bladder cancer cells Apoptosis (apoptosis) effect analysis
To determine whether the inhibition of growth and cell morphology of bladder cancer cells by treatment with Kombucha (K) and Citrus Kombucha (CK) was due to apoptosis, the cells were treated with non-invasive (superficial) bladder cancer cells T24 cells and high-risk superficial bladder cancer cells, 5637 cells, were treated for 24 hours with 0, 4, 6, 8 mg / PE-Annexin V Kit was used to quantitatively determine the induction of apoptosis-induced apoptosis.
When Annexin V is apoptotic, the membrane structure is destroyed at an early stage and phospholipids such as phosphatidylserine (PS) exclusively inside the cell are exposed to the outside of the cell. Annexin V binds to them Moxi flow cytometry was used to confirm that the cells are in the early stage of apoptosis.
Example 7-1: Kombucha Citrus Kom Bucha By treatment Nasal invasion (Superficial) on bladder cancer cells (T24 cell) Apoptosis (apoptosis) effect analysis
In 6 well plates (6-well plate) to 2 × 10 5 cells of the number / well (well) T24 cells were subcultured, and each of the combus and citrus subspecies samples were treated at 0, 4, 6 and 8 mg / ml and cultured for 24 hours. After culturing for 24 hours, the medium and cells were transferred to a tube and centrifuged at 1000 rpm for 2 minutes. Separated cells were washed with cold PBS (phosphate buffer saline), centrifuged again, and supernatant was removed. After removal of the supernatant, 1 × cold binding buffer was added to dilute the cells to 1 × 10 5 cells. 5 μl of PE-Annexin V was added thereto and vortexed vigorously. After incubation at 25 ° C for 15 minutes, 400 μl of 1 × binding buffer was added and the degree of induction of apoptosis was measured by FACS (Moxi flow cytometry, ORFLO, Cambridge, USA).
As shown in FIG. 11, the T24 cells as non-invasive (superficial) bladder cancer cells were treated with the comb cells and the citrus comb cells at the concentrations of 0, 4, 6 and 8 mg / ml, respectively. As a result, Apoptosis was induced in the order of 4.47%, 4.07%, 6.4%, and 11.1%, respectively. In the case of treatment with Citrus subtilis, apoptosis was observed in 3.5%, 6.87%, 30.97% and 97.4% I could. Especially, when treated with Citrus squamous carcass at a concentration of 8 mg / ml, the apoptotic cell ratio was 97.4%, and apoptosis-induced apoptosis was significantly increased ( p <0.05).
Example 7-2: Kombucha Citrus Kom Bucha The high risk of treatment was also found in superficial bladder cancer cells (5637 cells) Apoptosis ( apoptosis ) Effect analysis
In 6 well plates (6-well plate) to 2 × 10 5 cells of the number / well (well) 5637 cells were subcultured, and the combus carotid and citrus subspecies samples were treated at 0, 4, 6, and 8 mg / ml, respectively, for 24 hours. After culturing for 24 hours, the medium and cells were transferred to a tube and centrifuged at 1000 rpm for 2 minutes. Separated cells were washed with cold PBS (phosphate buffer saline), centrifuged again, and supernatant was removed. After removal of the supernatant, 1 × cold binding buffer was added to dilute the cells to 1 × 10 5 cells. 5 μl of PE-Annexin V was added thereto and vortexed vigorously. After incubation at 25 ° C for 15 minutes, 400 μl of 1 × binding buffer was added and the degree of induction of apoptosis was measured by FACS (Moxi flow cytometry, ORFLO, Cambridge, USA).
As shown in FIG. 12, when the cells were treated with high-risk superficial bladder cancer cells, 5637 cells, at a concentration of 0, 4, 6 and 8 mg / ml, ) Were 3.87%, 5.57%, 6.73% and 7.83%, respectively, and 3.87%, 6.27%, 7.3% and 15.73% respectively when treated with Citrus squamous cell carcinoma ( p < 0.05).
Through the analysis of apoptosis effect on the bladder cancer cells by the treatment of the comb and carcinoma cells, the cell death rate of the comb cells in the non-invasive (superficial) bladder cancer cell T24 cells was 11 %, Respectively. On the other hand, in the case of treatment with Citrus squamous carcass at the concentrations of 6 and 8 mg / ml, apoptosis induced apoptosis induction was 38% and 97%, respectively. On the other hand, in both high-risk superficial bladder cancer cells 5637 cells, both the comb and the citrus comb subunits were found to be less than 11% in apoptosis-induced apoptosis regardless of treatment concentration. Thus, it can be seen that the citrus comb subcomponent of the present invention can be usefully used for the prevention or treatment of bladder cancer of nasally invasive (superficial) bladder cancer, which is an early bladder cancer.
Example 8: Kombucha Citrus Kom Bucha Treatment of bladder cancer cells Apoptosis (apoptosis) related protein
In order to examine the apoptosis-related proteins and genes of bladder cancer cells by Kombucha (K) and Citrus Kombucha (CK), proteins were separated by size and then subjected to antigen-antibody reaction Western blot analysis was performed on the principle of detecting only specific proteins in whole proteins. The types of antibodies used in the Western blot analysis are shown in Table 4, and β-actin is a mixture of T24 cells of bladder cancer cells treated with Combusa and citrus subsp. And used as a control (internal control).
Specifically, T24 cells as non-invasive (superficial) bladder cancer cells and 5637 cells as high-risk superficial bladder cancer cells were divided into Petri dishes at a cell number of 1 × 10 6 cells / ml, Sub-samples were treated at 0, 4, 6, and 8 mg / ml, respectively, and cultured for 24 hours. After culturing for 24 hours, the cells treated with the comb and the citrus sub-samples were collected using a scraper. The recovered cells were washed with phosphate buffered saline (PBS). After washing, the cell lysate was added with protein lysis buffer to each cell sample, and the cells were disrupted and centrifuged at 1000 rpm for 2 minutes. The protein of each supernatant obtained after centrifugation was quantitated using BCA (bicinchoninic acid) and used as a sample.
The proteins in each of the supernatants obtained above were loaded equally into 12% SDS-PAGE (12% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis) gel and proteins were separated for 3 hours. The separated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane of 0.45 μm size for 2 hours and then the membrane was blocked with 5% skim milk blocking. After completion of the blocking, the membrane was washed with TBS-T (Tris Buffered Saline-Tween 20), and the primary antibody was reacted overnight at 4 ° C. After the overnight reaction, the membrane was washed with TBS-
As a result, as compared with the case of treatment with comb adjunct as shown in FIG. 13, when T24 cells, which are non-invasive (superficial) bladder cancer cells, were treated with citrus combs at a concentration of 6 and 8 mg / The expression of Bcl-2, an anti-apoptotic protein, was decreased and the expression of Bax, a pro-apoptotic protein, was not significantly different. In addition, the expression of the active cleaved caspase-3, cleved caspase-8 and cleved caspase-9 was increased in a concentration-dependent manner, Expression of the inactive forms of Pro caspase-3, Cleved caspase-8 and Cleved caspase-9 was decreased in a concentration-dependent manner, and caspase-3 it was confirmed that the cleaved PARP (cleaved PARP) expression was increased by cleavage of the tumor-promoting complex protein (PARP, poly-ADP ribose polymerase) by caspase-3. On the other hand, the apoptosis-related protein did not show any difference in expression when treated with combat.
As shown in FIG. 14, the expression levels of the apoptosis-related proteins in the high-risk superficial bladder cancer cells, 5637 cells, were compared with those of the control group. There was no difference in expression between the two groups.
In this study, we investigated the effect of citrus juice supplemented with citrus juice on the apoptosis of caspase-mediated T24 cells, a non-invasive (superficial) bladder cancer cell with low malignancy, compared with 5637 cells with high-risk superficial bladder cancer cells apoptosis), it can be seen that the citrus comb secondary of the present invention can be usefully used for the prevention or treatment of bladder cancer, which is an early bladder cancer.
In summary, through the above results, it was possible to confirm the antioxidant ability and the total polyphenol content of citrus squam carcinoma cultured with the addition of citrus juice, compared with that of the common squid carcinoma, and the growth of T24 cells as a non-invasive (superficial) bladder cancer Inhibition and regulation of apoptosis - inducing protein expression, it was found that the citrus subspecies can inhibit the progression of early bladder cancer and is effective for prevention and treatment.
Example 9: Statistical processing
The experiments performed in the present invention were repeated 3 times or more independently. The results of the experiments were analyzed using t -test analysis and ANOVA analysis using the SPSS Version 18.0 package program for statistical analysis The significance of the treatment group was verified using Dancan's multiple range test at P = 0.05 level.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150098278A KR101797813B1 (en) | 2015-07-10 | 2015-07-10 | Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150098278A KR101797813B1 (en) | 2015-07-10 | 2015-07-10 | Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170007637A KR20170007637A (en) | 2017-01-19 |
KR101797813B1 true KR101797813B1 (en) | 2017-11-16 |
Family
ID=57990843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150098278A KR101797813B1 (en) | 2015-07-10 | 2015-07-10 | Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101797813B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190138066A (en) | 2018-06-04 | 2019-12-12 | 줄리안 오베이도 바스퀘즈 크리스챤 | kombucha manufacturing method |
KR20200087500A (en) | 2019-01-11 | 2020-07-21 | 동아대학교 산학협력단 | Composition for preventing, improving or treating of bladder cancer comprising lauric acid derivatives |
KR102157466B1 (en) | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | Composition for preventing, improving or treating of bladder cancer comprising hexahydrotriazine derivatives |
KR20210098225A (en) | 2020-01-31 | 2021-08-10 | 제주대학교 산학협력단 | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha |
KR20220023092A (en) | 2020-08-20 | 2022-03-02 | (사)천수산약초연구회 | Method for preparing Kombucha fermented liquid using cudrania tricuspidata and use of Kombucha fermented liquid in metabolic syndrome-related diseases |
US11918020B2 (en) | 2021-05-17 | 2024-03-05 | Aquacultured Foods, Inc. | Food product comprising a co-culture of bacteria and fungi |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102050515B1 (en) | 2017-11-15 | 2019-11-29 | 에스케이바이오랜드 주식회사 | Cosmetic composition containing tangerine fermented broth with lactic acid bacteria |
KR102563452B1 (en) | 2020-12-01 | 2023-08-03 | 윤여민 | Process for preparing fermented kombucha with microbiome |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100482308B1 (en) | 2002-09-12 | 2005-04-14 | 학교법인 계명기독학원 | Method for production of Kombucha containg green-tea extract |
-
2015
- 2015-07-10 KR KR1020150098278A patent/KR101797813B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Comprehensive Reviews in Food Science and Food Safety. 2014. Vol. 13, pp. 538-550* |
International Journal of Food Sciences and Nutrition. 2014. Vol. 65, No. 7, pp. 893-898* |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190138066A (en) | 2018-06-04 | 2019-12-12 | 줄리안 오베이도 바스퀘즈 크리스챤 | kombucha manufacturing method |
KR20200087500A (en) | 2019-01-11 | 2020-07-21 | 동아대학교 산학협력단 | Composition for preventing, improving or treating of bladder cancer comprising lauric acid derivatives |
KR20210098225A (en) | 2020-01-31 | 2021-08-10 | 제주대학교 산학협력단 | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha |
KR102157466B1 (en) | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | Composition for preventing, improving or treating of bladder cancer comprising hexahydrotriazine derivatives |
KR20220023092A (en) | 2020-08-20 | 2022-03-02 | (사)천수산약초연구회 | Method for preparing Kombucha fermented liquid using cudrania tricuspidata and use of Kombucha fermented liquid in metabolic syndrome-related diseases |
US11918020B2 (en) | 2021-05-17 | 2024-03-05 | Aquacultured Foods, Inc. | Food product comprising a co-culture of bacteria and fungi |
Also Published As
Publication number | Publication date |
---|---|
KR20170007637A (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101797813B1 (en) | Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient | |
MX2007010408A (en) | Compositions comprising actinidia and methods of use thereof. | |
KR101734979B1 (en) | Composition for preventing and treating cancer, and enhancing the immune action | |
KR101931611B1 (en) | Composition for antioxidant, and anti-inflammation effect comprising Cirtus extract and Hylotelephium erythrostictum extract | |
KR101579820B1 (en) | Pharmaceutical compositions for the treatment of cancer metastasis or inhibition of metastasis containing Quassia undulata extracts as active fractions | |
KR101188581B1 (en) | Composition comprising Cyperus rotundus methalnol extracts for preventing or treating Sepsis | |
KR20150058698A (en) | Antioxidant composition containing purified bee venom | |
KR101418164B1 (en) | A pharmaceutical composition comprising extract of UV-induced rice for preventing or treating a colon cancer | |
KR102043454B1 (en) | Composition for preventing, ameliorating or treating anti-cancer drug-resistant lung cancer comprising gliotoxin as effective component | |
KR101982937B1 (en) | Composition for preventing and treating a cancer comprising Cnidium officinale Makion | |
KR101941368B1 (en) | Composition for preventing or treating cancer comprising Salvia militiorrhiza | |
KR102063321B1 (en) | Composition for Preventing or Treating Uterine Myoma Comprising Orostachys japonicus Extract | |
ES2906476B2 (en) | Ethanolic extract of Citrullus colocynthis seeds, method for obtaining it, pharmaceutical composition containing it and its use as an antitumor agent | |
US20090263521A1 (en) | Composition for the treatment of cancers and inhibition of metastasis containing extracts or fractions of the magnolia obovata | |
Kusumawati et al. | Pharmacological studies of the genus rice (Oryza L.): a literature review | |
KR102628997B1 (en) | Composition Comprising the Extract of Senna Alata for Preventing or Inhibiting Vascular Aging | |
KR102155713B1 (en) | Composition for preventing or treating cancer comprising sea cucumber extracts or fraction thereof, and trail protein | |
KR102109145B1 (en) | Composition for preventing, ameliorating or treating anti-cancer drug-resistant lung cancer comprising Pavetta indica extract, its fraction or 5,6-dehydrokawain isolated from the extract as effective component | |
KR20160103547A (en) | Antioxidant composition containing purified bee venom | |
KR102455428B1 (en) | Medical composition for preventing or treating cancer and health functional food | |
KR100519660B1 (en) | Pharmaceutical composition comprising genistein for treating nk/t cell lymphoma | |
KR20220151074A (en) | Composition for inhibiting proliferation of tumor comprising Sanguisorba officinalis extract as effective component | |
KR20210142068A (en) | A composition comprising the extract of Nephelium lappaceum seed or flavonoids isolated therefrom as an active ingredient of a senomorphic agent for inhibiting aging-related symptoms and for preventing and treating senescence-associated diseases | |
KR20220094941A (en) | Pharmaceutical composition for prevention and treatment of pancreatic cancer comprising extracts of Tamarindus indica L. hull | |
KR101558946B1 (en) | Compositions for inhibiting metastasis or preventing cancer comprising Illicium verum Hook.f. extract or fraction thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |